Jennifer Carlisle, MD

• Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

  • Phase

    II/III
  • Conditions

    Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
  • Location

    Winship Cancer Institute

• Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)

  • Phase

    III
  • Conditions

    Metastatic Non Small Cell Lung Cancer
  • Location

    Winship Cancer Institute

• Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.

  • Phase

    I/II
  • Conditions

    Small Cell Lung Cancer, Advanced Solid Malignant Tumor
  • Location

    Winship Cancer Institute

• A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

  • Phase

    I
  • Conditions

    Locally Advanced or Metastatic Solid Tumors, NSCLC, HNSCC, Melanoma, TNBC, Esophageal Cancer, Gastric Cancer, Cervical Cancer, Urothelial Carcinoma, Clear Cell RCC, HCC
  • Location

    Winship Cancer Institute

• Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer

  • Phase

    Early Phase I
  • Conditions

    Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
  • Location

    Emory University Hospital Midtown, Winship Cancer Institute

Back to the Drawing Board: Overcoming Resistance to PD-1 Blockade.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Impact of immunotherapy time-of-day infusion on survival and immunologic correlates in patients with metastatic renal cell carcinoma: a multicenter cohort analysis.

Journal for immunotherapy of cancer

Shifting Sociodemographic Characteristics of a Phase I Clinical Trial Population at an NCI-Designated Comprehensive Cancer Center in the Southeast.

The oncologist

Safety and efficacy of durvalumab after concurrent chemoradiation in Black patients with locally advanced non-small cell lung cancer.

Cancer

BA.5 bivalent booster vaccination enhances neutralization of XBB.1.5, XBB.1.16 and XBB.1.9 variants in patients with lung cancer.

NPJ vaccines

Advancing immunotherapy in small cell lung cancer.

Cancer

Characteristics and anatomic location of PD-1⁺TCF1⁺ stem-like CD8 T cells in chronic viral infection and cancer.

Proceedings of the National Academy of Sciences of the United States of America

Antibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivity to the SARS-CoV-2 WT Virus and Omicron Variant.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

A Phase 2 Study of Docetaxel, Ramucirumab, and Pembrolizumab for Patients With Metastatic or Recurrent Non-Small-Cell Lung Cancer (NSCLC) who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade.

Clinical lung cancer

Impact of radiation dose to the immune cells in unresectable or stage III non-small cell lung cancer in the durvalumab era.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Clinical outcome following checkpoint therapy in renal cell carcinoma is associated with a burst of activated CD8 T cells in blood.

Journal for immunotherapy of cancer

High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience.

JTO clinical and research reports

Antibody response to SARS-CoV-2 mRNA vaccine in lung cancer patients: Reactivity to vaccine antigen and variants of concern.

medRxiv : the preprint server for health sciences

EGFR L718V (+)/T790M (-) as a Mechanism of Resistance in Patients with Metastatic Non-small-cell Lung Cancer with EGFR L858R Mutations.

Clinical lung cancer

Tyrosine Kinase Inhibitors, Antibody-Drug Conjugates, and Proteolysis-Targeting Chimeras: The Pharmacology of Cutting-Edge Lung Cancer Therapies.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting

Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO).

Immunotherapy

YAP1 Expression in SCLC Defines a Distinct Subtype With T-cell-Inflamed Phenotype.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Efficacy and safety of immune checkpoint blockade in self-identified Black patients with advanced non-small cell lung cancer.

Cancer

An update on the immune landscape in lung and head and neck cancers.

CA: a cancer journal for clinicians

Considerations for cancer immunotherapy biomarker research during COVID-19.

Endocrine-related cancer

Integrating Genetic and Genomic Testing Into Oncology Practice.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting

An intra-tumoral niche maintains and differentiates stem-like CD8 T cells.

Nature

Improving outcomes for brain metastases in EGFR mutated NSCLC.

Translational lung cancer research

05/11/2024

Honest answers.

05/09/2024

Good

05/04/2024

We had a good visit, but will need more information to decide on a care plan. Again, the thoracic radiology report.

03/23/2024

Details to patient history was discussed thoroughly by all members of the team

03/20/2024

Excellent care and follow ups

03/18/2024

Dr. Carlisle showed exemplary compassion and concern for us. We look forward to working with her and her team

03/08/2024

She has been so supportive to me ad caring.

01/26/2024

Dr. Carlisle might have to be the most important person in my care team. Very thankful to be under her care.

01/14/2024

Dr. Carlisle and her team provide excellent care Moreover, they work with other teams at Emory and elsewhere to deliver great care.

01/09/2024

The doctor took a lot of time with me. Answered all my questions

12/24/2023

Dr. Carlilse is great as are all the members of her team. I am lucky to have Dr. Carlisle as my oncologist.

12/22/2023

Dr. Carlisle couldn't have been better... Friendly, knowledgeable, listened as well as spoke, sense of humor, the whole package.

12/03/2023

Dr. Carlisle and her team are excellent. I have no recommending them to anyone. Blood draw nurse was especially helpful explaining new port.

09/15/2023

Dr. Carlisle and her team are professional, efficient, and compassionate.

08/27/2023

Dr. Carlisle has always been very specific in the results of my labs and procedures. We discuss my medications and changes if necessary.

06/27/2023

Dr Carlisle is excellent discussing treatment options and answering my questions. I trust her judgement and know she will honestly answer my concerns and questions and give me her opinion of the best course of treatment as I go through each stage along the way.

06/13/2023

We were very impressed with Dr Carlisle. She spent nearly a full hour with us. I have never experienced this with any doctor before. I had a lot of questions, and she happily and completely answered all of them. She knows her stuff and I am pleased that she has a good amount of experience treating my particular cancer. The nutritionist was the same.

05/26/2023

Dr Carlisle is great, I'm confident of the quality and thoroughness of her care.

04/28/2023

The doctor showed that she cares about you as a patient.

01/28/2023

Horrible overall experience

01/27/2023

Doctor took time to answer all my questions in a clear way

11/10/2022

Always a pleasure working with Lindsey. She's knowledgeable, professional, and truly cares.

09/09/2022

Med staff is top notch. Not parking or counter staff

08/06/2022

Dr. Carlisle provided me with much needed information about my cancer diagnosis and treatment.

07/29/2022

Dr Carlisle was very professional. She answered all my questions and gave me very good advise.